Athero Review - Issue 2/2017
Comments on the Glagov study
Tomáš Kovárník, Jan Pudil, Kristýna Bayerová
The study ODYSSEY CHOICE I with alirocumab: more data on PCSK9 inhibition
Michal Vrablík, Eva Tůmová
Can we improve primary prevention of ischaemic heart disease? Which way?
Ján Murín, Miroslav Pernický, Martin Wawruch
Changes in the lipid spectrum in endocrinopathies
Patrícia Páleníková, Juraj Payer
2017 Issue 2
Most read in this issue
- What is the role of nutriceuticals in dyslipidemia management? Armolipid Plus
Remnant cholesterol: a fact or fiction?
Reflection on the problems related to remnant cholesterol
- Changes in the lipid spectrum in endocrinopathies
- Myths on diet and prevention of atherosclerosis